In VivoIN VITRO DIAGNOSTICS Financings Biocept Inc. Biocept Inc. (blood-based molecular diagnostics for solid tumors) netted $8.7mm through the sale of 4.3mm common shares at $2.15 (a slight discount) to
In VivoDevice Transactions Financing by device companies during the third quarter of 2016 totaled $3 billion, doubling Q2's $1.5 billion. As in the past two quarters, debt offerings continue to make up the h
In VivoCompany Changes BERTOLINO , Arthur P., MD, PhD To: Cellceutix Corp. , Pres. & CMO (June) From: Innovation Dermatologics Inc., CEO Phone: 978-236-8717 COLOMA , Jason V., PhD To: Corvus Pharm